Geron Corporation (GERN)
GERN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/0000950170-24-022056-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GERN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1996 |
| SEC CIK | 0000886744 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $237K |
| Net income | -$184.1M |
| Operating income | -$193.9M |
| Net margin | -77690.7% |
| Operating margin | -81832.9% |
| Revenue growth | -60.2% |
| Cash | $70.0M |
| Total assets | $394.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2560.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $69.2M cash; operating cash flow -$22.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 644,238,859 (2026-10-30); 638,355,275 a year earlier; 543,063,950 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $19K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $60.2M | $1.4M | $10.3M | $69.2M | $120.4M | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $57.5M | -$16.7M | -$15.8M | $62.6M | $120.1M | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $51.8M | -$3.6M | -$62.9M | $68.9M | $119.8M | Needs four quarters | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | Not filed | -$28.9M | -$22.1M | $77.6M | $119.5M | Needs four quarters | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $47.2M | -$18.4M | -$13.6M | $78.1M | $119.3M | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $49.0M | -$16.4M | -$27.4M | $77.7M | $119.0M | Needs four quarters | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $39.6M | -$19.8M | -$48.0M | $83.7M | $118.7M | Needs four quarters | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | Not filed | -$25.4M | -$43.9M | $79.0M | $118.5M | Needs four quarters | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.0% |
| 1 month | -19.2% |
| 3 months | -37.0% |
| Year to date | -26.5% |
| 1 year | -15.7% |
| From 52-week high | -50.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
| ABUS | Arbutus Biopharma Corporation | $4.04 | -1.22% | $619.3M |
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier